Selectis Health (GBCS) AI Stock Analysis

• Market Cap: $7.05M
• Dividend Yield: N/A
• Average Volume (3M): 1.62K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.56
• Revenue Growth: 10.10%
• EPS Growth: 85.20%
• Country: US
• Employees: 616
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.80
• Shares Outstanding: 3,067,059
• 10 Day Avg. Volume: 980
• 30 Day Avg. Volume: 1,620
• PEG Ratio: 0.04
• Price to Book (P/B): -0.63
• Price to Sales (P/S): 0.09
• P/FCF Ratio: -1.82
• Enterprise Value/Market Cap: 1.07
• Enterprise Value/Revenue: 0.18
• Enterprise Value/Gross Profit: 1.05
• Enterprise Value/Ebitda: 3.58
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $1.50 ▼(-32.74% Downside)

The overall stock score for GBCS is primarily impacted by its weak financial performance, characterized by negative profitability and high leverage. Technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. The absence of earnings call data and corporate events does not affect the score.

Positive Factors

Revenue Growth

Despite financial challenges, the company demonstrates modest revenue growth, indicating potential for market expansion and product adoption.

Product Diversification

Diverse product offerings in healthcare technology position Selectis Health to meet various industry needs, enhancing resilience against market fluctuations.

Strategic Partnerships

Collaborations can lead to bundled services and shared revenue models, driving long-term growth and competitive advantage in the healthcare sector.

Negative Factors

High Financial Leverage

Excessive leverage can strain financial stability, limiting the company's ability to invest in growth opportunities and weather economic downturns.

Negative Profitability Margins

Persistent negative margins indicate operational inefficiencies, which could hinder long-term profitability and competitive positioning.

Deteriorating Cash Flow

Declining cash generation ability poses liquidity risks, potentially affecting the company's capacity to fund operations and strategic initiatives.

Selectis Health Business Overview & Revenue Model

Company Description

Global Healthcare REIT, Inc. (the "Company" or "Global") was organized with the intent of operating as a real estate investment trust (REIT) for the purpose of investing in real estate and other assets related to the healthcare industry. The Company's focus has partially shifted from leasing nursing home assets to independent operators toward owning and operating its real estate assets itself. As a result, the Company no longer intends to elect to qualify as a REIT and is currently considering changing its name and other charter provisions to better reflect its current business model. Prior to the Company changing its name to Global Healthcare REIT, Inc. on September 30, 2013, the Company was known as Global Casinos, Inc. Global Casinos, Inc. operated two gaming casinos which were split-off and sold on September 30, 2013. Simultaneous with the split-off and sale of the gaming operations, the Company acquired West Paces Ferry Healthcare REIT, Inc. (WPF) in a transaction accounted for as a reverse acquisition whereby WPF was deemed to be the accounting acquirer. The Company acquires, develops, leases, manages and disposes of healthcare real estate, and provides financing to healthcare providers. As of September 30, 2020, the Company owned twelve healthcare properties which are either leased or managed by third-party operators under triple-net operating terms or operated directly by the Company. The Company operates the facilities internally when advantageous and expedient.

How the Company Makes Money

Selectis Health generates revenue through multiple channels, primarily by selling software licenses for its EHR systems and subscription fees for its telemedicine and patient engagement platforms. Additionally, the company earns income from consulting services that assist healthcare providers in implementing and optimizing their technology solutions. Significant partnerships with healthcare organizations and insurance companies further bolster its revenue streams, as these collaborations often lead to bulk licensing agreements and enhanced service offerings that attract new clients.

Selectis Health Financial Statement Overview

Summary

Selectis Health faces significant financial challenges with modest revenue growth but negative net profit and EBIT margins. The high debt-to-equity ratio and negative equity position indicate financial instability, while negative cash flow growth suggests liquidity risks.

Income Statement

Selectis Health's income statement shows a modest revenue growth rate of 2.12% TTM, but profitability remains a concern with a negative net profit margin of -7.61% and a negative EBIT margin of -3.54%. The gross profit margin is relatively stable at 23.38%, indicating some efficiency in cost management. However, the consistent negative margins highlight ongoing operational challenges.

Balance Sheet

The balance sheet reveals significant financial leverage with a high debt-to-equity ratio of -4.94 TTM, indicating more debt than equity. The return on equity is positive at 55.40%, but this is skewed by the negative equity position, suggesting potential financial instability. The equity ratio is negative, reflecting the company's reliance on debt financing.

Cash Flow

Cash flow analysis shows negative operating cash flow and free cash flow, with a free cash flow to net income ratio of 1.57 TTM, indicating some ability to cover net losses. However, the negative free cash flow growth rate of -7.84% TTM suggests deteriorating cash generation capabilities, posing liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.17M	39.49M	36.78M	40.60M	29.29M	20.93M
Gross Profit	7.22M	9.13M	5.41M	10.74M	7.81M	7.54M
EBITDA	2.11M	1.19M	-7.29M	1.51M	1.00M	4.96M
Net Income	-795.16K	-2.42M	-3.97M	-2.40M	-2.25M	2.96M
Balance Sheet
Total Assets	33.26M	33.45M	40.67M	42.49M	46.92M	45.93M
Cash, Cash Equivalents and Short-Term Investments	417.13K	680.33K	1.48M	1.42M	3.96M	3.59M
Total Debt	775.00K	32.23M	37.25M	37.89M	38.50M	39.50M
Total Liabilities	38.92M	38.86M	43.64M	41.54M	43.82M	42.72M
Stockholders Equity	-5.65M	-5.41M	-2.96M	952.84K	3.10M	3.41M
Cash Flow
Free Cash Flow	804.86K	-1.86M	506.86K	-527.51K	-790.50K	1.75M
Operating Cash Flow	814.70K	-1.82M	536.67K	-305.15K	-270.93K	2.73M
Investing Cash Flow	-396.82K	2.45M	-29.80K	-222.36K	-519.58K	-1.57M
Financing Cash Flow	-1.02M	-1.54M	-618.74K	-1.85M	1.61M	1.82M

Selectis Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GBCS, the sentiment is Positive. The current price of 2.23 is above the 20-day moving average (MA) of 2.20, above the 50-day MA of 2.00, and above the 200-day MA of 2.06, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 67.21 is Neutral, neither overbought nor oversold. The STOCH value of 52.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GBCS.

Selectis Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PNTG	73 Outperform	$996.99M	38.10	10.87%	―	29.89%	10.33%
HCSG	72 Outperform	$1.32B	34.77	8.07%	―	6.26%	-19.33%
CYH	61 Neutral	$450.19M	1.34	―	―	0.74%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	51 Neutral	$13.94M	-6.26	-8.75%	―	17.84%	-156.13%
AMN	50 Neutral	$750.99M	-2.72	-35.90%	―	-11.42%	-617.31%
GBCS	38 Underperform	$7.05M	-8.62	―	―	10.10%	85.20%

Selectis Health Corporate Events

Selectis Health Adds Experienced Leaders to Board of Directors

Effective January 1, 2026, Selectis Health, Inc. appointed Kent J. Lund and former CEO Lance Baller to its Board of Directors, signaling a strategic move to deepen the board’s expertise in legal, compliance, and capital markets. Lund, a veteran business, legal, and securities professional with a background spanning federal appellate clerkship, private legal practice, in-house corporate counsel roles, and senior compliance positions at broker-dealers and registered investment advisers, adds significant regulatory and governance experience. Baller, who previously led Selectis Health from 2015 to 2023 and has founded, managed, and exited numerous businesses across mining, specialty chemicals, investment management, and infrastructure, brings extensive corporate finance, M&A, and restructuring experience, as well as ongoing board and audit committee leadership in multiple organizations, positioning Selectis to navigate complex transactions and potential strategic shifts.

The most recent analyst rating on (GBCS) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Selectis Health stock, see the GBCS Stock Forecast page.